Spironolakton, doksazosyna czy bisoprolol- jaki czwarty lek w opornym nadciśnieniu tętniczym? Badanie PATHWAY 2 (Kongres ESC 2015)

The principal results of the Prevention And Treatment of Hypertension With Algorithm based therapY (PATHWAY) – Optimal treatment of drug resistant hypertension – PATHWAY 2. Presented at the ESC Congress 2015 by: Bryan Williams (London, UK)

Main results

  • In 314 patients, spironolactone had superior HSBP control compared to placebo (a reduction of 8.70 mm Hg, P<.001); doxazosin (a reduction of 4.03 mm Hg, P<0.001), and bisoprolol (a reduction of 4.48 mm Hg, P<0.001) …